BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11086230)

  • 1. Contraceptive progestins. Various 11-substituents combined with four 17-substituents: 17alpha-ethynyl, five- and six-membered spiromethylene ethers or six-membered spiromethylene lactones.
    Schoonen WG; Deckers G; de Gooijer ME; de Ries R; Mathijssen-Mommers G; Hamersma H; Kloosterboer HJ
    J Steroid Biochem Mol Biol; 2000 Oct; 74(3):109-23. PubMed ID: 11086230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals.
    Deckers GH; Schoonen WG; Kloosterboer HJ
    J Steroid Biochem Mol Biol; 2000 Oct; 74(3):83-92. PubMed ID: 11086227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives.
    Schoonen WG; Deckers GH; de Gooijer ME; de Ries R; Kloosterboer HJ
    J Steroid Biochem Mol Biol; 2000 Nov; 74(4):213-22. PubMed ID: 11162927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nestorone: a progestin with a unique pharmacological profile.
    Kumar N; Koide SS; Tsong Y; Sundaram K
    Steroids; 2000; 65(10-11):629-36. PubMed ID: 11108869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human progesterone receptor A and B isoforms in CHO cells. II. Comparison of binding, transactivation and ED50 values of several synthetic (anti)progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats.
    Schoonen WG; Dijkema R; de Ries RJ; Wagenaars JL; Joosten JW; de Gooyer ME; Deckers GH; Kloosterboer HJ
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):157-70. PubMed ID: 9605410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay.
    McRobb L; Handelsman DJ; Kazlauskas R; Wilkinson S; McLeod MD; Heather AK
    J Steroid Biochem Mol Biol; 2008 May; 110(1-2):39-47. PubMed ID: 18395441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays.
    Fuhrmann U; Slater EP; Fritzemeier KH
    Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A; Hahn DW; McGuire JL
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 7α-methyl-19-nortestosterone effectiveness alone or combined with progestins on androgen receptor mediated-transactivation.
    García-Becerra R; Ordaz-Rosado D; Noé G; Chávez B; Cooney AJ; Larrea F
    Reproduction; 2012 Feb; 143(2):211-9. PubMed ID: 22065861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency.
    Lemus AE; Enríquez J; García GA; Grillasca I; Pérez-Palacios G
    J Steroid Biochem Mol Biol; 1997 Jan; 60(1-2):121-9. PubMed ID: 9182866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
    Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
    Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor profiling and endocrine interactions of tibolone.
    de Gooyer ME; Deckers GH; Schoonen WG; Verheul HA; Kloosterboer HJ
    Steroids; 2003 Jan; 68(1):21-30. PubMed ID: 12475720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins.
    García-Becerra R; Cooney AJ; Borja-Cacho E; Lemus AE; Pérez-Palacios G; Larrea F
    J Steroid Biochem Mol Biol; 2004 Jun; 91(1-2):21-7. PubMed ID: 15261304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.
    Louw-du Toit R; Perkins MS; Hapgood JP; Africander D
    Biochem Biophys Res Commun; 2017 Sep; 491(1):140-146. PubMed ID: 28711501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives.
    Kloosterboer HJ; Vonk-Noordegraaf CA; Turpijn EW
    Contraception; 1988 Sep; 38(3):325-32. PubMed ID: 3139361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.
    Attardi BJ; Page ST; Hild SA; Coss CC; Matsumoto AM
    J Steroid Biochem Mol Biol; 2010 Feb; 118(3):151-61. PubMed ID: 19941958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of the estrogenic, androgenic, and progestagenic potential of two cyclic siloxanes.
    Quinn AL; Regan JM; Tobin JM; Marinik BJ; McMahon JM; McNett DA; Sushynski CM; Crofoot SD; Jean PA; Plotzke KP
    Toxicol Sci; 2007 Mar; 96(1):145-53. PubMed ID: 17175556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.
    Pasapera AM; Gutiérrez-Sagal R; García-Becerra R; Ulloa-Aguirre A; Savouret JF
    Endocrine; 2001 Dec; 16(3):217-25. PubMed ID: 11954666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
    Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL
    Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity.
    Attardi BJ; Hild SA; Reel JR
    Endocrinology; 2006 Jun; 147(6):3016-26. PubMed ID: 16497801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.